ABSTRACT
Galvanized steel surfaces are widely used in industry as a solution to prevent corrosion of steel tools that operate in outdoor or corrosive and oxidative environments. These objects are coated with a zinc protective layer deposited by hot dip galvanization. Turning the surface of galvanized steel tools into superhydrophobic may lead to very useful functionalities, although it may be a difficult task, because the preservation of the thin zinc layer is a claim. We propose herein the use of a bottom-up approach based on sandblasting, followed by sintering of zinc nanoparticles on the galvanized steel substrate, which allowed us to produce a zinc-made hierarchical structure required for superhydrophobicity. These samples acquired a double-scale structure that led to superhydrophobicity when they were later hydrophobized with a thin fluoropolymer layer. We found that sandblasting might be useful but not mandatory, unlike the sintering process, which was essential to reach superhydrophobicity. We found that, under certain experimental conditions, the surfaces showed outstanding water-repellent properties. We observed that the sandblasting on galvanized steel caused more damage than the sintering process. Sintering of low-melting-point metal nanoparticles was revealed as a promising strategy to fabricate functional metallic surfaces.
ABSTRACT
The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and being overweight are well established risk factors for severe disease. However, innate immunity plays a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural Killer (NK) cells are part of innate immunity and are important in the control of virus infection by killing infected cells and participating in the development of adaptive immunity. Therefore, we studied the short tandem repeat (STR) transmembrane polymorphisms of the major histocompatibility complex class I chain-related A (MICA), an NKG2D ligand that induces activation of NK cells, among other cells. We compared the alleles and genotypes of MICA in COVID-19 patients versus healthy controls and analyzed their relation to disease severity. Our results indicate that the MICA*A9 allele is related to infection as well as to symptomatic disease but not to severe disease. The MICA*A9 allele may be a risk factor for SARS-CoV-2 infection and symptomatic disease.
Subject(s)
COVID-19 , Histocompatibility Antigens Class I , COVID-19/genetics , COVID-19/immunology , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Humans , Major Histocompatibility Complex , Polymorphism, Genetic , SARS-CoV-2/immunologyABSTRACT
Cancer eradication and clinical outcome of immunotherapy depend on tumor cell immunogenicity, including HLA class I (HLA-I) and PD-L1 expression on malignant cells, and on the characteristics of the tumor microenvironment, such as tumor immune infiltration and stromal reaction. Loss of tumor HLA-I is a common mechanism of immune escape from cytotoxic T lymphocytes and is linked to cancer progression and resistance to immunotherapy with the inhibitors of PD-L1/PD-1 signaling. Here we observed that HLA-I loss in bladder tumors is associated with T cell exclusion and tumor encapsulation with stromal elements rich in FAP-positive cells. In addition, PD-L1 upregulation in HLA-I negative tumors demonstrated a correlation with high tumor grade and worse overall- and cancer-specific survival of the patients. These changes define common immuno-morphological signatures compatible with cancer immune escape and acquired resistance to therapeutic interventions across different types of malignancy. They also may contribute to the search of new targets for cancer treatment, such as FAP-expressing cancer-associated fibroblasts, in refractory bladder tumors.
Subject(s)
Histocompatibility Antigens Class I/immunology , Lymphocytes, Tumor-Infiltrating/immunology , T-Lymphocytes, Cytotoxic/immunology , Tumor Escape/immunology , Urinary Bladder Neoplasms/immunology , Adult , Aged , Aged, 80 and over , B7-H1 Antigen/immunology , Female , Humans , Immunotherapy/methods , Male , Middle Aged , Phenotype , Tumor Microenvironment/immunology , Young AdultABSTRACT
Four important topics about children and adolescents in our Primary Care activity are presented in this update document: support for breastfeeding, promotion of physical activity, prevention of child injuries due to traffic accidents, and screening for major depression.
Subject(s)
Accidents, Traffic , Primary Health Care , Adolescent , Child , HumansABSTRACT
The transformation and progression of myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia (sAML) involve genetic, epigenetic, and microenvironmental factors. Driver mutations have emerged as valuable markers for defining risk groups and as candidates for targeted treatment approaches in MDS. It is also evident that the risk of transformation to sAML is increased by evasion of adaptive immune surveillance. This study was designed to explore the immune microenvironment, immunogenic tumor-intrinsic mechanisms (HLA and PD-L1 expression), and tumor genetic features (somatic mutations and altered karyotypes) in MDS patients and to determine their influence on the progression of the disease. We detected major alterations of the immune microenvironment in MDS patients, with a reduced count of CD4+ T cells, a more frequent presence of markers related to T cell exhaustion, a more frequent presence of myeloid-derived suppressor cells (MDSCs), and changes in the functional phenotype of NK cells. HLA Class I (HLA-I) expression was normally expressed in CD34+ blasts and during myeloid differentiation. Only two out of thirty-six patients with homozygosity for HLA-C groups acquired complete copy-neutral loss of heterozygosity in the HLA region. PD-L1 expression on the leukemic clone was also increased in MDS patients. Finally, no interplay was observed between the anti-tumor immune microenvironment and mutational genomic features. In summary, extrinsic and intrinsic immunological factors might severely impair immune surveillance and contribute to clonal immune escape. Genomic alterations appear to make an independent contribution to the clonal evolution and progression of MDS.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Killer Cells, Natural/immunology , Leukemia, Myeloid, Acute/genetics , Myelodysplastic Syndromes/genetics , Myeloid-Derived Suppressor Cells/immunology , Adult , Aged , Aged, 80 and over , B7-H1 Antigen/metabolism , Carcinogenesis , Cellular Senescence , Disease Progression , Female , HLA-C Antigens/genetics , Humans , Immunologic Surveillance , Male , Middle Aged , Mutation/genetics , Tumor Escape , Tumor Microenvironment/immunology , Young AdultABSTRACT
BACKGROUND: Tumor human leukocyte antigen class I (HLA-I) expression plays an important role in T cell-mediated tumor rejection. Loss of HLA-I is associated with cancer progression and resistance to immunotherapy, including antibodies blocking programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling. Our objective was to analyze a correlation between HLA-I, tumor immune infiltration, and PD-L1/PD-1 axis in bladder cancer in association with the clinicopathologic features of patients. METHODS: We analyzed 85 cryopreserved bladder tumors by immunohistochemistry to investigate the expression of HLA-I, PD-L1, PD-1, CD3, CD8, and CXC chemokine receptor 4 (CXCR4). The results were correlated with tumor stage and other clinicopathologic variables of patients. RESULTS: We found a strong positive correlation between tumor HLA-I expression and infiltration with CD3+ and CD8 + T cells. PD-L1 expression was positive in 15.5% of tumors and heterogeneous in 40.5%, and was linked to a more advanced tumor stage. The majority of HLA-I-positive/heterogeneous tumors also expressed PD-L1 and PD-1, which were significantly correlated with each other and with lymphocyte infiltration. Interestingly, the analysis of the simultaneous expression of both markers revealed that 85.2% of tumors with a positive/heterogeneous HLA-I phenotype and negative for PD-L1 were mostly non-invasive, representing a 'tumor rejection' immune phenotype. CONCLUSIONS: High tumor HLA-I expression with absence of PD-L1 provides bladder cancer with an immune rejection mechanism. Evaluation of PD-L1 and HLA-I together should be considered in bladder cancer and may provide a new predictive biomarker of tumor invasiveness and of the response to 'immune checkpoint' therapy.
Subject(s)
B7-H1 Antigen/metabolism , CD8-Positive T-Lymphocytes/immunology , Histocompatibility Antigens Class I/metabolism , Lymphocytes, Tumor-Infiltrating/immunology , Muscle Neoplasms/immunology , Neoplasm Recurrence, Local/immunology , Urinary Bladder Neoplasms/immunology , Adult , Aged , Aged, 80 and over , B7-H1 Antigen/immunology , Biomarkers, Tumor/metabolism , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/pathology , Female , Follow-Up Studies , Histocompatibility Antigens Class I/immunology , Humans , Lymphatic Metastasis , Lymphocytes, Tumor-Infiltrating/metabolism , Lymphocytes, Tumor-Infiltrating/pathology , Male , Middle Aged , Muscle Neoplasms/metabolism , Muscle Neoplasms/pathology , Muscle Neoplasms/surgery , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Prognosis , Tumor Microenvironment , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/surgeryABSTRACT
Inflammation plays a central role in the pathophysiology of acute pancreatitis (AP). We hypothesized that changes in the function of key components of the inflammatory cascade, caused by genetic polymorphisms, could determine the development and/or severity of AP. We studied the following polymorphisms in 269 patients: IL23R rs11209026, TNF rs1800629, RIPK2 rs42490, NOD2 rs9302752, MCP1 rs1024611 and NFKB1 rs28362491. The rs11209026 A allele was related to the presence of AP (p = 0.007261; OR = 1 .523). Epistasis analysis revealed that AP susceptibility was increased by interaction between IL23R rs11209026 and TNF rs1800629 (p = 1.205 × 10-5; ORinteraction = 4.031). The rs42490-G allele was associated with an increased risk of severe pancreatitis (p = 0.01583; OR = 2.736), severe or moderately severe pancreatitis (p = 0.04206; OR = 1.609), and death (p = 0.03226; OR = 3.010). In conclusion, these results point to a plausible role for genetic polymorphisms in IL23R and RIPK2 in the development and severity of AP.
Subject(s)
Genotype , Pancreatitis/genetics , Receptor-Interacting Protein Serine-Threonine Kinase 2/genetics , Receptors, Interleukin/genetics , Aged , Aged, 80 and over , Case-Control Studies , Disease Progression , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Pancreatitis/mortality , Polymorphism, Single Nucleotide , Risk , Severity of Illness IndexABSTRACT
HLA class I (HLA-I) molecules play a crucial role in the presentation of tumor antigenic peptides to CD8+ T cells. Tumor HLA-I loss provides a route of immune escape from T cell-mediated killing. We analyzed HLA-I expression in 98 cryopreserved breast cancer tissues using a broad panel of anti-HLA-I antibodies. Genomic HLA-I typing was performed using DNA obtained from autologous normal breast tissue. Analysis of the loss of heterozygosity (LOH) in the HLA-I region of chromosome 6 (LOH-6) and in the ß2-microglobulin (B2M) region of chromosome 15 (LOH-15) was done by microsatellite amplification of DNA isolated from microdissected tumor areas. B2M gene sequencing was done using this DNA form HLA-I-negative tumors. Immunohistological analysis revealed various types of HLA-I alterations in 79 tumors (81%), including total HLA-I loss in 53 cases (54%) and partial loss in 16 samples (14%). In 19 cases (19%), HLA-I expression was positive. Using microsatellite analysis, we detected LOH in 36 cases out of 92 evaluated (39%), including 15 samples with only LOH-6, 14 with LOH-15, and seven tumors with LOH-6 and LOH-15 at the same time. Remarkably, we detected LOH-6 in eight tumors with positive HLA-I immunolabeling. We did not find any B2M mutations in HLA-I-negative breast tumors. In conclusion, LOH at chromosomes 6 and 15 has a high incidence in breast cancer and occurs in tumors with different HLA-I immunophenotypes. This common molecular mechanism of HLA-I alterations may reduce the ability of cytotoxic T lymphocytes to kill tumor cells and negatively influence the clinical success of cancer immunotherapy.
Subject(s)
Antigens, Neoplasm/genetics , Breast Neoplasms/genetics , Histocompatibility Antigens Class I/genetics , Loss of Heterozygosity/genetics , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm/immunology , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Chromosomes, Human, Pair 15/genetics , Chromosomes, Human, Pair 6/genetics , Female , Histocompatibility Antigens Class I/immunology , Histocompatibility Testing , Humans , Microsatellite Repeats/genetics , Middle Aged , beta 2-Microglobulin/geneticsABSTRACT
We wanted to analyze whether tumor HLA class I (HLA-I) expression influences the pattern of the immune cell infiltration and stromal cell reaction in the tumor microenvironment. Tumor tissues obtained from 57 patients diagnosed with lung carcinomas were analyzed for HLA expression and leukocyte infiltration. 28 patients out of the 57 were completely negative for HLA-I expression (49.1%) or showed a selective HLA-A locus downregulation (three patients, 5.2%). In 26 out of 57 tumors (47.8%) we detected a positive HLA-I expression but with a percentage of HLA-I negative cells between 10 and 25%. The HLA-I negative phenotype was produced by a combination of HLA haplotype loss and a transcriptional downregulation of ß2-microglobulin (ß2-m) and LMP2 and LMP7 antigen presentation machinery genes. The analysis and localization of different immune cell populations revealed the presence of two major and reproducible patterns. One pattern, which we designated "immune-permissive tumor microenvironment (TME)," was characterized by positive tumor HLA-I expression, intratumoral infiltration with cytotoxic T-CD8+ cells, M1-inflammatory type macrophages, and a diffuse pattern of FAP+ cancer-associated fibroblasts. In contrast, another pattern defined as "non-immune-permissive TME" was found in HLA-I negative tumors with strong stromal-matrix interaction, T-CD8+ cells surrounding tumor nests, a dense layer of FAP+ fibroblasts and M2/repair-type macrophages. In conclusion, this study revealed marked differences between HLA class I-positive and negative tumors related to tissue structure, the composition of leukocyte infiltration and stromal response in the tumor microenvironment.
Subject(s)
Carcinoma, Non-Small-Cell Lung/immunology , Gene Expression Regulation, Neoplastic/immunology , Genes, MHC Class I , HLA Antigens/immunology , Lung Neoplasms/immunology , Lymphocytes, Tumor-Infiltrating/immunology , T-Lymphocytes, Cytotoxic/immunology , Tumor Escape , Tumor Microenvironment/immunology , Aged , Aged, 80 and over , Antigen Presentation , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Cell Movement , Disease Progression , Down-Regulation , Endopeptidases , Female , Fibroblasts/pathology , Gelatinases/analysis , HLA Antigens/genetics , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Macrophages/pathology , Male , Membrane Proteins/analysis , Middle Aged , Neoplasm Proteins/analysis , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Serine Endopeptidases/analysis , Tumor Escape/genetics , Tumor Escape/immunologyABSTRACT
Most tumor cells derive from MHC-I-positive normal counterparts and remain positive at early stages of tumor development. T lymphocytes can infiltrate tumor tissue, recognize and destroy MHC class I (MHC-I)-positive cancer cells ("permissive" phase I). Later, MHC-I-negative tumor cell variants resistant to T-cell killing emerge. During this process, tumors first acquire a heterogeneous MHC-I expression pattern and finally become uniformly MHC-I-negative. This stage (phase II) represents a "non-permissive" encapsulated structure with tumor nodes surrounded by fibrous tissue containing different elements including leukocytes, macrophages, fibroblasts, etc. Molecular mechanisms responsible for total or partial MHC-I downregulation play a crucial role in determining and predicting the antigen-presenting capacity of cancer cells. MHC-I downregulation caused by reversible ("soft") lesions can be upregulated by TH1-type cytokines released into the tumor microenvironment in response to different types of immunotherapy. In contrast, when the molecular mechanism of the tumor MHC-I loss is irreversible ("hard") due to a genetic defect in the gene/s coding for MHC-I heavy chains (chromosome 6) or beta-2-microglobulin (B2M) (chromosome 15), malignant cells are unable to upregulate MHC-I, remain undetectable by cytotoxic T-cells, and continue to grow and metastasize. Based on the tumor MHC-I molecular analysis, it might be possible to define MHC-I phenotypes present in cancer patients in order to distinguish between non-responders, partial/short-term responders, and likely durable responders. This highlights the need for designing strategies to enhance tumor MHC-I expression that would allow CTL-mediated tumor rejection.
Subject(s)
Histocompatibility Antigens Class I/immunology , Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , Tumor Escape/immunology , Animals , Humans , ImmunotherapyABSTRACT
BACKGROUND AIMS: Despite the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), the procedure is still associated with high toxicity in patients with refractory graft-versus-host disease (GvHD). Mesenchymal stromal cells (MSCs) are a new mode of therapy in the context of allo-HSCT. The objective of this study was to evaluate the safety and feasibility of the use of adipose tissue-derived MSCs (AT-MSCs) in patients with chronic GvHD. METHODS: Fourteen patients with moderate (n = 7) or severe (n = 7) chronic GvHD received 1 × 106/kg (group A, n = 9) or 3 × 106/kg (group B, n = 5) AT-MSCs with cyclosporine and prednisone as first-line therapy. RESULTS: Ten of the 14 patients were able to continue under the protocol: 80% were in complete remission, and 100% were off of steroids at week 56. The remaining 4 patients either worsened from chronic GvHD (n = 3) or abandoned the study (n = 1). At the end of the study, 11 of 14 patients are alive (overall survival 71.4%, median survival of 45.3 weeks). No suspected unexpected serious adverse reactions occurred during the trial. Neither relapse of underlying disease nor mortality due to infection was observed in this cohort. Biological studies showed increased CD19, CD4 and tumor necrosis factor-α with a temporary decrease in natural killer cells. DISCUSSION: AT-MSCs, in combination with immunosuppressive therapy, may be considered feasible and safe and likely would have an impact on the course of chronic GvHD. More studies are warranted to understand the potential benefits of AT-MSCs in these patients.
Subject(s)
Adipose Tissue/cytology , Graft vs Host Disease/therapy , Mesenchymal Stem Cell Transplantation/methods , Adult , Cyclosporine/therapeutic use , Female , Humans , Immunosuppressive Agents/therapeutic use , Killer Cells, Natural , Male , Mesenchymal Stem Cell Transplantation/adverse effects , Mesenchymal Stem Cells , Middle Aged , Prednisone/therapeutic use , Treatment Outcome , Tumor Necrosis Factor-alpha/metabolismABSTRACT
OBJECTIVES: Positive autoantibody (AAB) titres are commonly encountered in autoimmune hepatitis (AIH) and in a proportion of drug-induced liver injury (DILI) patients. The underlying mechanism for selective AAB occurrence in DILI is unknown, but could be associated with variations in immune-associated genes. Hence, we aimed to analyse human leucocyte antigen (HLA) allele compositions in DILI with positive (+) and negative (-) AAB titres and in AIH patients. METHODS: High-resolution genotyping of HLA class I (A, B, C) and II (DRB1, DQB1) loci was performed on 207 DILI and 50 idiopathic AIH patients and compared with 885 healthy Spanish controls. RESULTS: Compared with controls, HLA-B*08:01 [44 vs. 9.7%, P=3.7E-13/corrected P-value (Pc)=1.0E-11], C*07:01 (46 vs. 24%, P=6.4E-04/Pc=0.012), DRB1*03:01 (58 vs. 21.5%, P=5.0E-09/Pc=1.0E-07) and DQB1*02:01 (56 vs. 22%, P=6.8E-08/Pc=9.0E-07) were significantly more frequent in AIH patients. The HLA-A*01:01 frequency was increased in the same population, but did not reach significance after Bonferroni's correction (34 vs. 19%, P=0.02/Pc=0.37). Fifty-eight of 207 DILI patients presented positive titres for at least one AAB (predominantly antinuclear antibody 76% and antismooth muscle antibody 28%). There was a tendency towards higher representation of DRB1*14:01 and DQB1*05:03 in DILI AAB+ compared with DILI AAB- (13.8 vs. 4.0%, P=0.02/Pc=0.5; 13.8 vs. 4.7%, P=0.04/Pc=0.5). CONCLUSION: The presence of HLA alleles B*08:01, C*07:01, DRB1*03:01, DQB1*02:01 and possibly A*01:01 enhances the risk of AIH (type 1) in Spanish patients. These alleles form part of the ancestral haplotype 8.1. HLA-DRB1*14:01 and DQB1*05:03 could potentially increase the risk of positive AAB (particularly antinuclear antibody) in Spanish DILI patients.
Subject(s)
Autoantibodies/metabolism , Chemical and Drug Induced Liver Injury/immunology , Hepatitis, Autoimmune/immunology , Histocompatibility Antigens Class II/genetics , Histocompatibility Antigens Class I/genetics , Adult , Aged , Aged, 80 and over , Chemical and Drug Induced Liver Injury/genetics , Female , Genetic Predisposition to Disease , Hepatitis, Autoimmune/genetics , Humans , Male , Middle Aged , Spain , White People/geneticsABSTRACT
Reduced expression of HLA class I is an important immune escape mechanism from cytotoxic T cells described in various types of malignancy. It often correlates with poor prognosis and resistance to therapy. However, current knowledge about the frequency, underlying molecular mechanisms, and prognostic value of HLA class I and II alterations in prostate cancer (PC) is limited. Immunohistochemical analysis demonstrated that 88 % of the 42 studied cryopreserved prostate tumors have at least one type of HLA alteration as compared to adjacent normal prostate epithelium or benign hyperplasia. Total loss of HLA-I expression found in 50 % of tumors showed an association with increased incidence of tumor relapse, perineural invasion, and high D'Amico risk. The remaining HLA-I-positive tumors demonstrated locus and allelic losses detected in 26 and 12 % of samples, respectively. Loss of heterozygosity at chromosome 6 was detected in 32 % of the studied tumors. Molecular analysis revealed a reduced expression of B2M, TAP2, tapasin and NLRC5 mRNA in microdissected HLA-I-negative tumors. Analysis of twelve previously unreported cell lines derived from neoplastic and normal epithelium of cancerous prostate revealed different types of HLA-I aberration, ranging from locus and/or allelic downregulation to a total absence of HLA-I expression. The high incidence of HLA-I loss observed in PC, caused by both regulatory and structural defects, is associated with more aggressive disease development and may pose a real threat to patient health by increasing cancer progression and resistance to T-cell-based immunotherapy.
Subject(s)
Histocompatibility Antigens Class I/immunology , Immunotherapy/methods , Prostatic Neoplasms/immunology , beta 2-Microglobulin/immunology , Humans , Male , Neoplasm Recurrence, LocalABSTRACT
The adsorbed mass of polymers on surfaces with different chemistry is presented, and the related adsorption mechanism is discussed. Strong and weak polyelectrolytes of negative and positive charge are studied, as well as an uncharged polymer. Self-assembled monolayers of alkanethiols on gold are used in reflectometry and quartz crystal microbalance (QCM-D) experiments as adsorbing substrates bearing different terminal moieties, namely, methyl, hydroxyl, carboxyl, and amine groups. The various polymer-surface combinations allow the systematic investigation of the role of surface chemistry and polymer charge on adsorbed amount. Interactions of different nature and range drive polymer adsorption: the measured adsorbed amounts reveal information about their relative contribution. When electrostatic chain-surface attraction is present, the largest adsorbed masses are observed. However, significant mass is measured even when an electrostatic barrier to adsorption is present, suggesting the importance of forces of nonelectrostatic origin, which include both hydrophobic interactions and specific forces acting at short distances. This mechanism results in large adsorbed amounts for the adsorption of weak polyelectrolytes, and it is apparent especially in the adsorption behavior of a neutral polymer.
ABSTRACT
Cancer cells escape T-cell-mediated destruction by losing human leukocyte antigen (HLA) class I expression via various mechanisms, including loss of beta2-microglobulin (ß2m). Our study illustrates the immune escape of HLA class I-negative tumor cells and chronological sequence of appearance of tumor ß2m gene mutation in successive lesions obtained from a patient with metastatic melanoma. We observed a gradual decrease in HLA expression in consecutive lesions with few HLA-negative nodules in the primary tumor and the emergence of a totally negative lesion at later stages of the disease. We detected loss of ß2m in ß2m-negative nests of the primary tumor caused by a combination of two alterations: (i) a mutation (G to T substitution) in codon 67 in exon 2 of ß2m gene, producing a stop codon and (ii) loss of the second gene copy by loss of heterozygosity (LOH) in chromosome 15. The same ß2m mutation was found in a homogeneously ß2m-negative metastasis 10 months later and in a cell line established from a biopsy of a postvaccination lymph node. Microsatellite analysis revealed the presence of LOH in chromosomes 6 and 15 in tumor samples, showing an accumulation of chromosomal loss at specific short tandem repeats in successive metastases during disease progression. HLA loss correlated with decreased tumor CD8+ T-cell infiltration. Early incidence of ß2m defects can cause an immune selection and expansion of highly aggressive melanoma clones with irreversible genetic defects causing total loss of HLA class I expression and should be taken into consideration as a therapeutic target in the development of cancer immunotherapy protocols.
Subject(s)
Histocompatibility Antigens Class I/biosynthesis , Melanoma/genetics , Tumor Escape/genetics , beta 2-Microglobulin/genetics , Aged , Cell Line, Tumor , Flow Cytometry , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Humans , Immunohistochemistry , Loss of Heterozygosity , Melanoma/immunology , Melanoma/pathology , Mutation , Neoplasm Invasiveness/genetics , Neoplasm Invasiveness/pathology , Neoplasm Metastasis , Reverse Transcriptase Polymerase Chain Reaction , Tumor Escape/immunology , beta 2-Microglobulin/immunologyABSTRACT
Self-assembled monolayers of thiols on gold are employed to study the role of surface chemistry on adsorption of polyelectrolytes to solid substrates. The suitability of these substrates is demonstrated in optical reflectivity, which combines high sensitivity to the possibility to precisely control the hydrodynamic conditions at the solid/water interface. Therefore, this system allows the determination of both the adsorbed amount and the kinetics of adsorption. The behavior of two representative strong polyelectrolytes of opposite charge is discussed as a function of pH and of concentration of a monovalent electrolyte in aqueous solutions. The application of equivalent substrates with varying surface chemistry sheds light on the role of different energetic contributions driving polyelectrolyte adsorption.
ABSTRACT
The petal effect is identified as a non-wetting state with high drop adhesion. The wetting behavior of petal surfaces is attributed to the papillose structure of their epidermis, which leads to a Cassie-Baxter regime combined with strong pinning sites. Under this scenario, sessile drops are pearl shaped and, unlike lotus-like surfaces, firmly attached to the surface. Petal surfaces are used as inspiration for the fabrication of functional parahydrophobic surfaces such as antibacterial or water-harvesting surfaces. In this work, two types of rose petals were replicated by using a templating technique based in Polydimethylsiloxane (PDMS) nanocasting. The topographic structure, the condensation mechanism under saturated environments and the wetting properties of the natural rose petal and their negative and positive replicas were analyzed. Finally, we performed prospective ice adhesion studies to elucidate whether petal-like surfaces may be used as deicing solutions.
Subject(s)
Fabaceae , Rosa , Surface Properties , Rosa/chemistry , Prospective Studies , WettabilityABSTRACT
BACKGROUND & AIMS: Several pharmaceutical compounds have been shown to exert inhibitory effects on the bile salt export pump (BSEP) encoded by the ABCB11 gene. We analysed the combined effect on drug-induced liver injury (DILI) development of the ABCB11 1331T>C polymorphism and the presence of specific chemical moieties, with known BSEP inhibiting properties, in the causative drug. METHODS: Genotyping using a TaqMan 5' allelic discrimination assay was performed in 188 Spanish DILI patients, 219 healthy controls and 91 sex-, age- and drug-matched controls. A chemical structure analysis was performed for each individual causative drug. RESULTS: The CC genotype was significantly associated with hepatocellular damage [odds ratio (OR) = 2.1, P = 0.001], particularly in NSAID DILI cases (OR = 3.4, P = 0.007). In addition, the CC genotype was found to be significantly linked to DILI development from drugs causing <50% BSEP inhibition (OR = 1.8, Pc = 0.011). Of the BSEP inhibitory chemical moieties, 59% of the causative drugs contained a carbocyclic system with at least one aromatic ring, corresponding to 61% of the total cases. The C allele was significantly more frequent in DILI cases containing this chemical moiety, which appear to be conditioned on the ABCB11 1331T>C polymorphism in the absence of other BSEP inhibitory structures. CONCLUSION: Patients carrying the C allele in the ABCB11 1331T>C polymorphism are at increased risk of developing hepatocellular type of DILI, when taking drugs containing a carbocyclic system with aromatic rings.
Subject(s)
ATP-Binding Cassette Transporters/genetics , Chemical and Drug Induced Liver Injury/genetics , Drug-Related Side Effects and Adverse Reactions/genetics , Genetic Predisposition to Disease/genetics , Pharmaceutical Preparations/chemistry , Polymorphism, Single Nucleotide/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 11 , Acids, Carbocyclic/chemistry , Female , Gene Frequency , Genotype , Humans , Hydrocarbons, Aromatic/chemistry , Male , Odds Ratio , Quantitative Structure-Activity Relationship , SpainSubject(s)
Autistic Disorder/diagnosis , Developmental Disabilities/diagnosis , Hearing Disorders/diagnosis , Vision Disorders/diagnosis , Adolescent , Child , Child, Preschool , Early Diagnosis , Humans , Immunization , Infant , Infant, Newborn , Infant, Premature , Infant, Very Low Birth Weight , SpainABSTRACT
Despite a lack of evidence, a bone marrow aspirate differential of 500 cells is commonly used in the clinical setting. We aimed to test the performance of 200-cell counts for daily hematological workup. In total, 660 consecutive samples were analyzed recording differentials at 200 and 500 cells. Additionally, immunophenotype results and preanalytical issues were also evaluated. Clinical and statistical differences between both cutoffs and both methods were checked. An independent control group of 122 patients was included. All comparisons between both cutoffs and both methods for all relevant types of cells did not show statistically significant differences. No significant diagnostic discrepancies were demonstrated in the contingency table analysis. This is a real-life study, and some limitations may be pointed out, such as a different sample sizes according to the type of cell in the immunophenotype analysis, the lack of standardization of some preanalytical events, and the relatively small sample size of the control group. The comparisons of differentials by morphology on 200 and 500 cells, as well as by morphology (both cutoffs) and by immunophenotype, are equivalent from the clinical and statistical point of view. The preanalytical issues play a critical role in the assessment of bone marrow aspirate samples.